COLLStockCOLLEGIUM PHARMACEUTICAL, INC
Verdicts genuinely change. Free email alert the moment COLL's does — no target price to set, unlike a price alert.
Near limit Ratio screen, 6 of 7 decided standards passing. AAOIFI is within 3 points of its line. Even if it crossed, the majority verdict would stay Not compliant, because it is held (Zoya rates it not compliant, and our ratio screen does not overrule another screener's finding). What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
COLLEGIUM PHARMACEUTICAL, INC (COLL) is currently considered not halal (non-compliant), per our in-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
435 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →
How the status reached this point
Non-compliant since Nov 18, 2026
First seen by our daily status check on Nov 18, 2026; it read Compliant on Nov 17, 2026, so the change landed between those two checks.
$25.55 — last close we recorded while it was still Compliant, Nov 17, 2026
Held it before Nov 18, 2026?
This site’s guidance, not a fatwa: sell within a reasonable time, and when you sell, give away any gain above the last close while it was still Compliant ($25.55), plus any dividends received since. AAOIFI’s standard does not set that reference price; it is how this site suggests drawing the line. For a ruling that applies to you, ask a qualified scholar.
Dividends from while it was still compliant are purified the usual way, by the impermissible share of the company’s income.
Work out that purification →- Nov 18, 2026 Compliant → Non-compliant6 of 7 decided standards pass; AAOIFI debt ratio 30.8%; held: Zoya rates it not compliant, and our screen does not overrule another screener's doubt.; figures as of Sep 30, 2026
- Nov 17, 2026 Tracking began Nothing before this date is on record.
Read once a day from the status this page publishes, last on Nov 21, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $794.0M as of 2026-11-18.
Business activity: cleared (no excluded categories detected)
AAOIFI Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 30.79% | 30.00% | Fail(0.8pp over) |
| Interest-bearing investments | 20.87% | 30.00% | Pass(9.1pp buffer) |
| Non-permissible income | 1.45% | 5.00% | Pass(3.6pp buffer) |
Usmani Pass 5 of 5 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.67% | 33.00% | Pass(21.3pp buffer) |
| Interest-bearing investments | 7.91% | 33.00% | Pass(25.1pp buffer) |
| Non-liquid assets | 77.27% | at least 20.00% | Pass(57.3pp above the floor) |
| Non-permissible income | 1.45% | 5.00% | Pass(3.6pp buffer) |
| Net liquid assets per share | $-126.6M | under mkt cap $794.0M | Pass |
MSCI Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.67% | 33.33% | Pass(21.7pp buffer) |
| Cash + interest-bearing securities | 7.91% | 33.33% | Pass(25.4pp buffer) |
| Accounts receivable | 22.73% | 33.33% | Pass(10.6pp buffer) |
| Non-permissible income | 1.45% | 5.00% | Pass(3.6pp buffer) |
FTSE Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.40% | 33.33% | Pass(21.9pp buffer) |
| Cash + interest-bearing securities | 7.91% | 33.33% | Pass(25.4pp buffer) |
| Accounts receivable | 22.73% | 50.00% | Pass(27.3pp buffer) |
| Non-permissible income | 1.45% | 5.00% | Pass(3.6pp buffer) |
Dow Jones Islamic Market Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.16% | 33.00% | Pass(9.8pp buffer) |
| Cash + interest-bearing securities | 15.70% | 33.00% | Pass(17.3pp buffer) |
| Accounts receivable | 29.44% | 33.00% | Pass(3.6pp buffer) |
| Non-permissible income | 1.45% | 5.00% | Pass(3.6pp buffer) |
S&P Shariah Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.35% | 33.00% | Pass(9.7pp buffer) |
| Cash + interest-bearing securities | 15.82% | 49.00% | Pass(33.2pp buffer) |
| Accounts receivable | 29.68% | 49.00% | Pass(19.3pp buffer) |
| Non-permissible income | 1.45% | 5.00% | Pass(3.6pp buffer) |
MSCI M-Series Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.35% | 33.33% | Pass(10.0pp buffer) |
| Cash + interest-bearing securities | 15.82% | 33.33% | Pass(17.5pp buffer) |
| Accounts receivable | 45.50% | 49.00% | Pass(3.5pp buffer) |
| Non-permissible income | 1.45% | 5.00% | Pass(3.6pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from COLL's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $780.6M | 2025-12-31 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtShort and long-term borrowings | $239.0M | 2026-09-30 | ConvertibleLongTermNotesPayable |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $165.7M | 2026-09-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, MarketableSecuritiesCurrent |
| Total assetsBalance sheet total | $2.1B | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $794.0M | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $1.1B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $1.1B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $11.3M | 2025-12-31 | InvestmentIncomeNet |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-05, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-02-26, period ended 2025-12-31. Screened 2026-11-18.
-
Total assets$2.1B
Assets· period ended 2026-09-30 · 10-Q filed 2026-11-05 -
Interest-bearing debt$239.0M
ConvertibleLongTermNotesPayable· period ended 2026-09-30 · 10-Q filed 2026-11-05 -
Cash and interest-bearing securities$165.7M
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents$165.7M · period ended 2026-09-30 · 10-Q filed 2026-11-05MarketableSecuritiesCurrent$0 · period ended 2026-09-30 · 10-Q filed 2026-11-05 -
Receivables$310.8M
AccountsReceivableNetCurrent· period ended 2026-09-30 · 10-Q filed 2026-11-05 -
Revenue$780.6M
RevenueFromContractWithCustomerExcludingAssessedTax· period ended 2025-12-31 · 10-K filed 2026-02-26 -
Interest income (non-permissible)$11.3M
InvestmentIncomeNet· period ended 2025-12-31 · 10-K filed 2026-02-26 -
Market cap$794.0MMarket quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-18 · not a filing figure, so no link
7 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.
What changed, and when
Verdict history for COLL. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-11-17 Unverified → Pass filing re-screen
Tracked since 2026-09-07.
What would change the status
The headline verdict is the majority of the decided ratio standards — 6 pass and 1 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-18.
Within 3 points of the line
- AAOIFI debt ratio: 0.8pp over
AAOIFI is within 3 points of its line. Even if it crossed, the majority verdict would stay Not compliant, because it is held (Zoya rates it not compliant, and our ratio screen does not overrule another screener's finding).
The ratios that move with the share price
AAOIFI's debt ratio is $244.5M debt (operating leases included, as the screen counts it) over a market cap of $794.0M (as of 2026-11-18), 30.8% against a 30% line.
It would pass if the market cap rose above $815.0M (+3%), about $26.23 a share against $25.55 implied by the screen's own figures.
AAOIFI would then pass; the majority verdict would stay Not compliant (7 of 7 decided standards passing), because it is held (Zoya rates it not compliant, and our ratio screen does not overrule another screener's finding).
At the screen's market cap, it would take $6.3M less debt to clear the line.
AAOIFI would then pass; the majority verdict would stay Not compliant (7 of 7 decided standards passing, counting every standard that divides the same figure), because it is held (Zoya rates it not compliant, and our ratio screen does not overrule another screener's finding).
AAOIFI's investments ratio is $165.7M cash and interest-bearing investments over a market cap of $794.0M (as of 2026-11-18), 20.9% against a 30% line.
It would fail if the market cap fell to $552.4M (-30%), about $17.77 a share against $25.55 implied by the screen's own figures.
AAOIFI would then fail; the majority verdict would stay Not compliant (6 of 7 decided standards passing), because it is held (Zoya rates it not compliant, and our ratio screen does not overrule another screener's finding).
At the screen's market cap, cash and interest-bearing investments would have to rise by $72.5M to reach the line.
AAOIFI would then fail; the majority verdict would stay Not compliant (5 of 7 decided standards passing, counting every standard that divides the same figure), because it is held (Zoya rates it not compliant, and our ratio screen does not overrule another screener's finding).
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Drug Manufacturers - Specialty & Generic listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| GALDYGalderma Group AG - ADR | $47.7B | — |
| HLNHaleon plc - ADR | $44.4B | — |
| NBIXNeurocrine Biosciences, Inc. | $15.9B | — |
| RDYDr. Reddy`s Laboratories Ltd. - ADR | $10.1B | — |
| ALKSAlkermes plc | $7.9B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold COLL
10 of the 261 funds whose filed holdings we currently hold own COLL shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns COLL.
You may already own itWidely held U.S. index funds. If you own one, you own COLL through it. None of them is a Shariah fund; the last column is our look-through of each.
| Fund | COLL in fund | Fund compliant by weight |
|---|---|---|
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.00% | 54% |
| VTI VANGUARD TOTAL STOCK MARKET INDEX FUND | 0.00% | 54% |
| SCHB Schwab U.S. Broad Market ETF | 0.00% | 53% |
| Fund | COLL in fund | Fund compliant by weight |
|---|---|---|
| LSSCX Loomis Sayles Small Cap Value Fund | 0.76% | 35% |
| ACSV American Century Small Cap Value Insights ETF | 0.15% | 32% |
| BDSIX BlackRock Advantage Small Cap Core Fund Also BDSKX | 0.05% | 35% |
| VIEIX VANGUARD EXTENDED MARKET INDEX FUND | 0.01% | 42% |
| VHCIX VANGUARD HEALTH CARE INDEX FUND | 0.01% | 73% |
| KCXVX Knights of Columbus U.S. ALL CAP INDEX FUND | 0.00% | 52% |
| VITNX VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND | 0.00% | 54% |
Sorted by COLL’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names COLL once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Israel Englander | Millennium Management | $52M | 0.0% | 2026-09-30 |
| Peter Brown | Renaissance Technologies | $31M | 0.0% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $14M | 0.0% | 2026-09-30 |
| Chuck Royce | Royce & Associates | $5M | 0.0% | 2026-09-30 |
| Third Avenue Management | Third Avenue Management | $5M | 0.8% | 2026-09-30 |
| Steven Cohen | Point72 Asset Management | $5M | 0.0% | 2026-09-30 |
| David Shaw | D. E. Shaw & Co. | $1M | 0.0% | 2026-09-30 |
| Joel Greenblatt | Gotham Asset Management | $1M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 53.70 | NEUTRAL |
| Stochastic %K (14) | 43.87 | NEUTRAL |
| CCI (20) | 47.12 | NEUTRAL |
| Williams %R (14) | -56.13 | NEUTRAL |
| MACD (12,26,9) | 0.05 | BUY |
| ROC (10) | 2.11 | BUY |
| Momentum (10) | 0.51 | BUY |
| EMA (10) | 25.01 | SELL |
| SMA (10) | 25.11 | SELL |
| EMA (20) | 24.55 | BUY |
| SMA (20) | 24.44 | BUY |
| EMA (30) | 24.31 | BUY |
| SMA (30) | 23.90 | BUY |
| EMA (50) | 24.56 | BUY |
| SMA (50) | 23.25 | BUY |
| EMA (100) | 26.79 | SELL |
| SMA (100) | 27.03 | SELL |
| EMA (200) | 32.00 | SELL |
| SMA (200) | 31.61 | SELL |
About COLLEGIUM PHARMACEUTICAL, INC
Healthcare · Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 43 |
| ⏰ 4H | BEARISH | 37 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-17 · Asset managers net 895049 (-19081)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.